NAA Services for Anti-TRANK1 IgG Antibodies
Creative Biolabs is a pioneer company in the NAA (natural autoantibodies) services market. With our professional scientists committed to research, we offer a full range of anti-TRANK1 IgG antibodies marker services for the diagnosis of schizophrenia. Our experienced scientists will take part in every step of your program to accelerate your project development.
Background of Anti-TRANK1 IgG Antibodies
Tetratricopeptide repeat and ankyrin repeat-containing 1 (TRANK1) is a human protein encoded by the TRANK1 gene localized in the short arm of chromosome 3, 3p22.2. Although the biological functions of TRANK1 largely remain unclear, autoantibodies against the TRANK1 protein (also named as lupus brain antigen 1) was demonstrated to be closely implicated to systemic lupus erythematosus (SLE) and schizophrenia. The TRANK1 protein was identified in murine SLE in 1998. Besides, evidence suggested that this autoantigen operates in the immune-pathogenesis of some neurologic manifestations of murine SLE. Through a Genome-wide association study, TRANK1 also has been indicated to be related to Bipolar disorder.
The Role of Anti-TRANK1 IgG Antibodies in Schizophrenia
Schizophrenia, a kind of mental disorder, is a highly heritable disease with complex modes of transmission. A previous study analysis confirmed that 108 genetic loci significantly associated with the risk of this disease. The expression levels of the candidate genes in most loci were found to be the highest in brain tissues and B-lymphocytes (CD20⁺ and CD19⁺ cells) over 50 analyzed human tissues and cell lines, supporting the hypothesis that schizophrenia is associated with immunological component during its development.
According to a recent study published in Schizophrenia Bulletin, patients with schizophrenia were shown to have altered antibody plasma concentrations against protein fragments of schizophrenia-correlated genes, among which the increased anti-TRANK1 IgG immunoglobulin may serve as a biomarker for the disease diagnosis. Recent research showed that interferon (IFN)-α could up-regulate the expression of the TRANK1 gene in differentiated hepatic cells by activation of the STAT-JAK pathway. Therefore, an increase in anti-TRANK1 IgG levels may disrupt IFN-mediated immune function in schizophrenia.
Fig.1 Possible mechanisms of immune-mediated causation of psychosis (Schizophrenia). (Khandaker, 2015)
What We Can Do About NAA?
Creative Biolabs provides comprehensive NAA services with first-rate technology platforms and prominent scientists, these services including NAA detection, NAA profiling, NAA affinity measurement, NAA epitope mapping, and paratope mapping. Moreover, a wide range of NAA products and related application services are also within our capabilities.
Features of Our Services
- State-of-the-art platform
- Outstanding scientists
- High efficiency and timely manner
- Cost-effective services
Creative Biolabs is specialized in the natural autoantibodies detections that are suitable for a number of immune diseases. In addition to schizophrenia, areas of research provided here include other types of diseases, such as cancer, apoptosis, neurobiology, autoimmune diseases, cardiovascular diseases, infectious diseases, and so on. Moreover, we offer customized solutions for our clients to meet every specific research requirement. Please contact us to experience the value of our expert services.
Reference:
- Khandaker, G.M.; et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015, 2(3), 258-270.